Medium reagent SensiScreen®

for cancersfor nucleic acidsfor PCR

Combining simplex or multiplex capabilities, SensiScreen® delivers profound sensitivity and flexibility by assisting in analysing somatic mutations. SensiScreen® provides suitable treatment suggestions based on a patient’s mutational status INTRODUCTION TO SENSISCREEN® Somatic mutations occur with different frequencies in cancers such as colorectal, lung, or malignant melanoma. The Somatic mutations affect a patient’s response to the cancer treatment, which puts incredibly high demands on treatment planners to make the right choice quickly. SensiScreen® takes that responsibility upon itself by setting high standards that ensure sensitive and precise analysis of each patient, so treatment plans can be provided on well-analyzed and validated data. The assay is available in 2 formats: Analysis of liquid biopsies Analysis of FFPE biopsies